Drug-induced interstitial lung disease: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System from 2004 to 2021.

Authors:
Jiang T; Su H; Xu J; Li C; Zhang N and 7 more

Journal:
Ther Adv Drug Saf

Publication Year: 2024

DOI:
10.1177/20420986231224227

PMCID:
PMC10823853

PMID:
38293566

Journal Information

Full Title: Ther Adv Drug Saf

Abbreviation: Ther Adv Drug Saf

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pharmacology & Pharmacy

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"The authors declare that there is no conflict of interest."

Evidence found in paper:

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Chongqing Clinical Pharmacy Key Specialties Construction Project [Grant No. 425Z41] and Chongqing Traditional Chinese Medicine Research Project (Joint project of Chongqing Health Commission and Science and Technology Bureau) [Grant No. 2023ZDXM032]."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025